News | October 15, 2014

Novartis' Investigational Heart Failure Drug Cut Death by 20 Percent

Novartis' Investigational Heart Failure Drug Cut Death by 20 Percent Treatment performed better than ACE-inhibitor in PARADIGM-HF trial

October 15, 2014 — Novartis Pharmaceuticals Canada Inc. revealed, in the largest heart failure study to date, that its investigational heart failure medicine, LCZ696, was superior to the ACE-inhibitor enalapril on key endpoints. The results were released at the 2014 European Society of Cardiology (ESC) Congress and published simultaneously in the New England Journal of Medicine.

In PARADIGM-HF, patients with heart failure and reduced ejection fraction (HF-REF) who were given LCZ696 were more likely to remain alive and have less re-hospitalization for heart failure than those given the ACE-inhibitor enalapril. Patients received LCZ696 or enalapril combined with the current best treatment regimen for heart failure treatment. The safety and efficacy of LCZ696 is still under investigation, and market authorization has not yet been obtained in Canada.

"The results of the PARADIGM study showed a reduction in hospitalizations for heart failure, a reduction in cardiovascular mortality and a reduction in total mortality when added to optimal therapy. It also improved the quality of life of patients in the trial," said cardiologist Jean-Lucien Rouleau, M.D., of the Montreal Heart Institute, a member of the PARADIGM-HF executive committee and a co-author of the study article. "These results are important given that one in every five or six of the Canadian population, over the age of 40, will experience heart failure. The PARADIGM-HF results are promising and may have a major impact in the way we manage heart failure in the future."

The PARADIGM-HF results showed the investigational treatment LCZ696, when added to current optimal care and compared to adding the ACE-inhibitor enalapril to optimal care, reduced:

  • the risk of death from cardiovascular causes by 20 percent (p=0.00004);
  • heart failure hospitalizations by 21 percent (p=0.00004); and
  • the risk of all-cause mortality by 16% (p=0.0005).


Overall there was a 20 percent risk reduction on the primary endpoint, a composite measure of CV death or heart failure hospitalization (p=0.0000002).

"Given the increasing prevalence, the high hospitalization rate and mortality in heart failure, there is a great need for new treatment alternatives in Canada and around the world,'' said Jean Godin, M.D., chief scientific officer and vice president, clinical and regulatory affairs, Novartis Pharmaceuticals Canada. "These results show the importance of pursuing research and development efforts to further improve the health outcomes of patients affected by this condition."

LCZ696, a twice-a-day tablet being investigated for heart failure, has a unique mode of action which is thought to reduce the strain on the failing heart. It acts to enhance the protective neurohormonal systems of the heart while simultaneously suppressing the RAAS system.

Analysis of the safety data from PARADIGM-HF showed side effects were manageable in the study. Fewer patients on LCZ696 discontinued study medication for any adverse event compared to those on enalapril (10.7 percent versus 12.3 percent, respectively, p=0.03). The LCZ696 group had more hypotension and non-serious angioedema but less renal impairment, hyperkalemia and cough than the enalapril group.

Novartis plans to pursue filings for marketing authorizations in different jurisdictions around the world, starting late in 2014 and continuing in 2015.

For more information: www.novartis.com

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init